市場調查報告書

類血友病(VWD)- 市場洞察,流行病學,市場預測 2028年

Von Willebrand Disease (VWD) - Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 524402
出版日期 內容資訊 英文 177 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類血友病(VWD)- 市場洞察,流行病學,市場預測 2028年 Von Willebrand Disease (VWD) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年11月01日內容資訊: 英文 177 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的類血友病(VWD)的2017年的罹患數為3萬3,758人,同年的市場規模估算為約3億9,720萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的類血友病(VWD)市場調查,疾病概要和現行的治療方法,已上市治療藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,性別、年齡、病型的患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊的總括性彙整。

目錄

第1章 簡介

第2章 類血友病(VWD)市場概要

  • 類血友病(VWD)的市場佔有率(成果值)
  • 類血友病(VWD)的市場佔有率(預測值)

第3章 疾病背景和概要:類血友病(VWD)

  • 簡介
  • 症狀
  • 區分
  • 病因
  • 臨床症狀
  • 遺傳的基礎
  • 病理學
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的類血友病(VWD)的總患病數

第5章 類血友病(VWD)的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 類血友病(VWD)的患病數
    • 類血友病(VWD)的患病數:性別
    • 類血友病(VWD)的患病數:各病型
    • 類血友病(VWD)的患病數:各年齡
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 治療流程、現行治療

  • 診斷及疾病管理上臨床治療指南(2012年)
  • 美國國立衛生研究所及國立心肺血液研究所(NHLBI)的VWD診斷、評估、管理
  • 英國血友病中心醫生會的診斷及管理指南

第7章 未滿足需求

第8章 已上市治療藥

  • Key Cross Competition
  • Vonvendi:Shire
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 臨床趨勢
    • 臨床實驗資訊
    • 安全性和有效性
    • 產品簡介
  • Voncento:CSL Behring
  • Humate-P/Haemate P:CSL Behring
  • Wilate:Octapharma
  • Wilfactin/Wilfact:LFB Biomedicaments
  • Desmopressin:Ferring Pharmaceuticals
  • Alphanate:Grifols Biological Inc.
  • Fanhdi:Grifols Biological Inc.

第9章 類血友病(VWD):主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的市場規模
  • 主要7個國家的市場規模:各治療藥物

第10章 美國的類血友病(VDW)市場預測

  • 市場規模
  • 市場規模:各治療藥物

第11章 歐盟5國及日本的類血友病(VDW)市場預測

  • 德國
    • 市場規模
    • 市場規模:各治療藥物
  • 法國
    • 市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 市場規模
    • 市場規模:各治療藥物
  • 英國
    • 市場規模
    • 市場規模:各治療藥物
  • 日本
    • 市場規模
    • 市場規模:各治療藥物

第12章 市場成長要素

第13章 市場障礙

第14章 附錄

第15章 DelveInsight的服務內容

第16章 免責聲明

第17章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0068

DelveInsight's 'Von Willebrand Disease (VWD)-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, France, Italy, Spain , and the United Kingdom), and Japan.

Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.

Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 0-18 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 19-44 years reported higher diagnosed prevalence than that of people belonging to other age groups.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Von Willebrand Disease (VWD)-Disease Understanding and Treatment Algorithm

Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process.

Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. Inherited forms are further subdivided into Type 1, 2, and 3 along with a pseudo-VWD. Platelet type disorder which in turn describes their pathophysiology. Type 1 is easily distinguished from type 3 by its milder deficiency and is characterized by a decreased quantity of vWF whereas Type 2 is distinguished on the basis of functional or qualitative deficiencies.

Von Willebrand Disease (VWD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain , and the United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 2017-2028.

Von Willebrand disease (VWD) Drug Chapters

The current therapeutic landscape of Von Willebrand disease can be divided into three major categories based on the class of drugs administered, they are; Non-replacement Therapy using desmopressin (DDAVP) to increase the plasma concentration of vWF, Replacement Therapy using plasma-derived coagulation factor concentrates (Humate-P, Alphanate, Immunate, and Wilate), and Adjunct Therapy using primarily anti-fibrinolytics, such as Tranexamic Acid (Cyclokapron).

A new category of recombinant coagulation factor concentrates -Vonvendi (Shire) has recently entered the replacement therapy segment. The approved (and their generic versions) as well as off-label products that are being used for the treatment of von Willebrand Disease, and contributing toward the market revenue, belong to either of these above-mentioned therapeutic classes.

Non-replacement therapy includes Desmopressin, which has been used as the first-line of treatment mostly for patients suffering from the Type 1 variants and a few Type-2 cases. Stimate (CSL Behring GmbH), DDAVP (Sanofi-Aventis), and Octostim (CSL Behring GmbH) with desmopressin acetate being the active ingredient are some of the drugs which belong to this category. The gradual emergence of virally-inactivated FVIII concentrates containing VWF for the treatment of hemophilia A proved a more optimal replacement therapeutic option for patients with VWD. Currently, they form the second-line of treatment especially during severe bleeding episodes of Type 1 variant as well as Type 2 and Type 3. In the United States, VWD is typically treated with either Humate-P (CSL Behring) or Wilate (Octapharma) or Alphanate (Grifols), which is identical to Fanhdi, made in Spain. Adjunct or supportive therapies mainly include antifibrinolytic agents, such as tranexamic acid (Cyclokapron) and amiococaproic acid (Amicar) which work by inhibiting the interaction of plasminogen with fibrin, thus preventing the degradation of the fibrin clot.

Von Willebrand disease (VWD) Market Outlook

According to DelveInsight, the market of Von Willebrand disease (VWD) in 7MM was found to be approximately USD 397.20 million in 2017. Among the EU5 countries, the United Kingdom had the highest market size with USD 61.62 million in 2017, while Spain had the lowest market size of Von Willebrand Disease with USD 6.37 million in 2017.

Von Willebrand disease (VWD) Drugs Uptake

Overall, the increasing diagnosed prevalence of the disease along with the promising expanded recombinant therapies will fuel the market during the forecasted period of 2019-2028 with some of the major players in the VWD treatment market being Shire Plc. (earlier Baxalta), CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.

The recent launch of Shire's Vonvendi/Veyvondi in the US and the expected launch in EU in 2019 have the potential to create a significant positive shift in the von Willebrand Disease market size. Expected launch of Wilfactin (LFB Biomedicaments) in 2021 (will file in the US) will also create a positive impact on the VWD market in US.

Von Willebrand disease (VWD) Report Insights

  • Patient Population by total diagnosed cases
  • Gender-specific diagnosed population
  • Type-specific diagnosed population
  • Age-specific diagnosed population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Von Willebrand disease (VWD) Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Von Willebrand disease (VWD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Von Willebrand disease (VWD) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand disease (VWD) market.
  • To understand the future market competition in the Von Willebrand disease (VWD) market.

Table of Contents

1. Key Insights

2. Von Willebrand Disease (VWD): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of VWD in 2017
  • 2.2. Total Market Share (%) Distribution of VWD in 2028

3. Disease Background and Overview: Von Willebrand Disease (VWD)

  • 3.1. Introduction
  • 3.2. Symptoms of Von Willebrand disease
  • 3.3. Classification of Von Willebrand disease
  • 3.4. Causes of Von Willebrand disease (VWD)
  • 3.5. Clinical Manifestations of Von Willebrand disease (VWD)
  • 3.6. Genetic Basis of Von Willebrand disease
  • 3.7. Pathophysiology of Von Willebrand disease (VWD)
  • 3.8. Diagnosis of Von Willebrand disease
  • 3.9. Diagnostic Guidelines of Von Willebrand disease (VWD)
    • 3.9.1. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health
    • 3.9.2. The diagnosis of von Willebrand disease: a guideline from the UK Hemophilia Centre Doctor's Organization

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease

5. Country Wise-Epidemiology of von Willebrand Disease

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United States
    • 5.1.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States
    • 5.1.4. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States
    • 5.1.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany
      • 5.2.1.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
      • 5.2.1.4. Type-Specific Diagnosed Prevalence of von Willebrand Disease in Germany
      • 5.2.1.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in France
      • 5.2.2.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in France
      • 5.2.2.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France
      • 5.2.2.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy
      • 5.2.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy
      • 5.2.3.4. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy
      • 5.2.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain
      • 5.2.4.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
      • 5.2.4.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain
      • 5.2.4.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
      • 5.2.5.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the UK
      • 5.2.5.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom
      • 5.2.5.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
  • 5.3. Japan
    • 5.3.1. Assumptions and rationale
    • 5.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan
    • 5.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan
    • 5.3.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan
    • 5.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. 2012 Clinical Practice Guideline on the Evaluation and Management of von Willebrand Disease (VWD)
  • 6.2. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health
  • 6.3. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

7. Unmet Needs

8. Marketed Drugs

  • 8.1. Key Cross Competition
  • 8.2. Vonvendi: Shire
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages and Disadvantages
    • 8.2.5. Clinical Development
    • 8.2.6. Clinical Trials Information
    • 8.2.7. Safety and Efficacy
    • 8.2.8. Product Profile
  • 8.3. Voncento: CSL- Behring
    • 8.3.1. Drug Description
    • 8.3.2. Mechanism of Action
    • 8.3.3. Regulatory Milestones
    • 8.3.4. Advantages and Disadvantages
    • 8.3.5. Clinical Development
    • 8.3.6. Clinical Trials Information
    • 8.3.7. Safety and Efficacy
    • 8.3.8. Product Profile
  • 8.4. Humate-P/Haemate P: CSL Behring
    • 8.4.1. Drug Description
    • 8.4.2. Mechanism of Action
    • 8.4.3. Regulatory Milestones
    • 8.4.4. Advantages and Disadvantages
    • 8.4.5. Safety and Efficacy
    • 8.4.6. Product Profile
  • 8.5. Wilate: Octapharma
    • 8.5.1. Drug Description
    • 8.5.2. Mechanism of Action
    • 8.5.3. Regulatory Milestones
    • 8.5.4. Advantages and Disadvantages
    • 8.5.5. Clinical Development
    • 8.5.6. Clinical Trials Information
    • 8.5.7. Safety and Efficacy
    • 8.5.8. Product Profile
  • 8.6. Wilfactin/Wilfact: LFB Biomedicaments
    • 8.6.1. Drug Description
    • 8.6.2. Mechanism of Action
    • 8.6.3. Regulatory Milestones
    • 8.6.4. Advantages and Disadvantages
    • 8.6.5. Product Profile
  • 8.7. Desmopressin: Ferring Pharmaceuticals
    • 8.7.1. Drug Description
    • 8.7.2. Mechanism of Action
    • 8.7.3. Regulatory Milestones
    • 8.7.4. Advantages and Disadvantages
    • 8.7.5. Product Profile
  • 8.8. Alphanate: Grifols Biological Inc.
    • 8.8.1. Drug Description
    • 8.8.2. Mechanism of Action
    • 8.8.3. Regulatory Milestones
    • 8.8.4. Advantages and Disadvantages
    • 8.8.5. Safety and Efficacy
    • 8.8.6. Product Profile
  • 8.9. Fanhdi: Grifols Biological Inc.
    • 8.9.1. Drug Description
    • 8.9.2. Mechanism of Action
    • 8.9.3. Regulatory Milestones
    • 8.9.4. Advantages and Disadvantages
    • 8.9.5. Safety and Efficacy
    • 8.9.6. Product Profile

9. Von Willebrand Disease: 7 Major Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Size of Von Willebrand Disease in 7MM
  • 9.3. Market Size by therapies of Von Willebrand Disease in 7MM

10. The United States Market Outlook

  • 10.1. United States Market Size
    • 10.1.1. Total Market size of Von Willebrand Disease
    • 10.1.2. Market Size by Therapies

11. EU-5 Countries: Market Outlook

  • 11.1. Germany
    • 11.1.1. Total Market size of von Willebrand Disease in Germany
    • 11.1.2. Market Size by Therapies
  • 11.2. France
    • 11.2.1. Total Market size of Von Willebrand Disease
    • 11.2.2. Market Size by Therapies
  • 11.3. Italy
    • 11.3.1. Total Market size of von Willebrand Disease
    • 11.3.2. Market Size by Therapies
  • 11.4. Spain
    • 11.4.1. Total Market size of von Willebrand Disease
    • 11.4.2. Market Size by Therapies
  • 11.5. United Kingdom
    • 11.5.1. Total Market size of Von Willebrand Disease
    • 11.5.2. Market Size by Therapies
  • 11.6. Japan: Market Outlook
    • 11.6.1. Total Market size of von Willebrand Disease
    • 11.6.2. Market Size by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Tables

  • Table 1 Classification of von Willebrand disease
  • Table 2 Sub-Classification of von Willebrand disease Type 2A
  • Table 3 Level of Evidence
  • Table 4 Total Diagnosed Prevalent Patient Population of Von Willebrand Disease in the 7MM (2017-2028)
  • Table 5 Total Diagnosed Prevalent Population of Von Willebrand Disease in the United States (2017-2028)
  • Table 6 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 7 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 8 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Table 9 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2017-2028)
  • Table 10 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 11 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 12 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Table 13 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2017-2028)
  • Table 14 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 15 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 16 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Table 17 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2017-2028)
  • Table 18 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 19 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 20 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Table 21 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2017-2028)
  • Table 22 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 23 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 24 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Table 25 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2017-2028)
  • Table 26 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 27 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 28 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Table 29 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2017-2028)
  • Table 30 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Table 31 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Table 32 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Table 33 Treatment of von Willebrand Disease
  • Table 34 Indications for Replacement Therapy in VWD
  • Table 35 List of Marketed Drugs Analysis
  • Table 36 List of Other Plasma Derived Products
  • Table 37 Vonvendi, Clinical Trial Description, 2019
  • Table 38 Voncento, Clinical Trial Description, 2019
  • Table 39 Wilate, Clinical Trial Description, 2019
  • Table 40 7 Major Market Size of Von Willebrand Disease in USD Million (2017-2028)
  • Table 41 Market size by therapies of Von Willebrand Disease by therapies in 7MM, in USD Million (2017-2028)
  • Table 42 United States Market Size of Von Willebrand Disease in USD Million (2017-2028)
  • Table 43 Market size of Von Willebrand Disease by therapies in the United States, in USD Million (2017-2028)
  • Table 44 Market Size of Von Willebrand Disease in Germany, in USD Million (2017-2028)
  • Table 45 Market size of Von Willebrand Disease by therapies in Germany, in USD Million (2017-2028)
  • Table 46 Market Size of Von Willebrand Disease in France, in USD Million (2017-2028)
  • Table 47 Market size of Von Willebrand Disease by therapies in France, in USD Million (2017-2028)
  • Table 48 Market Size of Von Willebrand Disease in Italy, in USD Million (2017-2028)
  • Table 49 Market size of Von Willebrand Disease by therapies in Italy, in USD Million (2017-2028)
  • Table 50 Market Size of Von Willebrand Disease in Spain, in USD Million (2017-2028)
  • Table 51 Market size of Von Willebrand Disease by therapies in Spain, in USD Million (2017-2028)
  • Table 52 Market Size of Von Willebrand Disease in the UK, in USD Million (2017-2028)
  • Table 53 Market size of Von Willebrand Disease by therapies in the UK, in USD Million (2017-2028)
  • Table 54 Market Size of Von Willebrand Disease in Japan, in USD Million (2017-2028)
  • Table 55 Market size of Von Willebrand Disease by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 The structure of VWF
  • Figure 2 Biosynthesis and Function of von Willebrand Factor
  • Figure 3 Symptoms of Subtypes of Type 2
  • Figure 4 Biosynthesis and Function of von Willebrand Factor
  • Figure 5 Type 2 VWD Variants.
  • Figure 6 Structure and function of pre-pro VWF
  • Figure 7 Pathophysiological Mechanisms and Classification of von Willebrand Disease
  • Figure 8 Initial hemostasis laboratory evaluation
  • Figure 9 Algorithm proposed for the diagnosis and classification of VWD
  • Figure 10 Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2017-2028)
  • Figure 11 Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 12 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 13 Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 14 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2017-2028)
  • Figure 15 Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2017-2028)
  • Figure 16 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 17 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 18 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2017-2028)
  • Figure 19 Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2017-2028)
  • Figure 20 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 21 Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 22 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in France (2017-2028)
  • Figure 23 Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2017-2028)
  • Figure 24 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 25 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 26 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2017-2028)
  • Figure 27 Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2017-2028)
  • Figure 28 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 29 Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 30 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2017-2028)
  • Figure 31 Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2017-2028)
  • Figure 32 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 33 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 34 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2017-2028)
  • Figure 35 Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2017-2028)
  • Figure 36 Gender-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Figure 37 Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Figure 38 Age-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2017-2028)
  • Figure 39 Treatment scheme for Von Willebrand Disease
  • Figure 40 Unmet Needs of Von Willebrand Disease
  • Figure 41 Marketed Drugs
  • Figure 42 7 Major Market Size of Von Willebrand Disease in USD Million (2017-2028)
  • Figure 43 7 Major Market Size by therapies of Von Willebrand Disease in USD Million (2017-2028)
  • Figure 44 Market Size of Von Willebrand Disease in the United States, USD Millions (2017-2028)
  • Figure 45 Market size of Von Willebrand Disease by therapies in the US, in USD Million (2017-2028)
  • Figure 46 Market Size of Von Willebrand Disease in Germany, USD Millions (2017-2028)
  • Figure 47 Market Size of Von Willebrand Disease by therapies, in Germany, in USD Million (2017-2028)
  • Figure 48 Market Size of Von Willebrand Disease in France, USD Millions (2017-2028)
  • Figure 49 Market Size of Von Willebrand Disease by therapies, in France, in USD Million (2017-2028)
  • Figure 50 Market Size of Von Willebrand Disease in Italy, USD Millions (2017-2028)
  • Figure 51 Market Size of Von Willebrand Disease by therapies in Italy, in USD Million (2017-2028)
  • Figure 52 Market Size of Von Willebrand Disease in Spain, USD Millions (2017-2028)
  • Figure 53 Market Size of Von Willebrand Disease by therapies in Spain, in USD Million (2017-2028)
  • Figure 54 Market Size of Von Willebrand Disease in the UK, USD Millions (2017-2028)
  • Figure 55 Market Size of Von Willebrand Disease by therapies in the UK, in USD Million (2017-2028)
  • Figure 56 Market Size of Von Willebrand Disease in Japan, USD Millions (2017-2028)
  • Figure 57 Market Size of Von Willebrand Disease by therapies in Japan, in USD Million (2017-2028)
  • Figure 58 Market Drivers
  • Figure 59 Market Barriers
Back to Top